Stahl J P, Bru J P, Fredj G, Brammer K W, Malleret M R, Micoud M
Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S612-6. doi: 10.1093/clinids/8.supplement_5.s612.
Concentrations of sulbactam in the CSF of 18 patients with bacterial meningitis who were undergoing treatment with intravenous (iv) ampicillin were determined. Six patients received single doses of sulbactam (1 g) and 12 patients received multiple doses (four times daily) by the iv route at various intervals before lumbar punctures were performed to monitor their condition. Concentrations of sulbactam up to 12 micrograms/ml were detected in the CSF between 1 and 4 hr after dosing, the higher levels being present in the CSF of patients with the most severe meningeal inflammation. There were no significant differences in the concentrations achieved after single or multiple doses of sulbactam, and the concentrations were generally similar to the concurrent concentrations of ampicillin. It is concluded that these results as well as the antibacterial properties of sulbactam plus ampicillin support the evaluation of this combination as an alternative in the treatment of bacterial meningitis.
测定了18例正在接受静脉注射氨苄西林治疗的细菌性脑膜炎患者脑脊液中的舒巴坦浓度。6例患者接受单次剂量的舒巴坦(1g),12例患者在进行腰椎穿刺以监测病情前,于不同时间间隔通过静脉途径接受多次剂量(每日4次)的舒巴坦。给药后1至4小时,脑脊液中检测到的舒巴坦浓度高达12微克/毫升,脑膜炎症最严重的患者脑脊液中舒巴坦水平更高。单次或多次剂量的舒巴坦给药后所达到的浓度无显著差异,且这些浓度通常与同时期的氨苄西林浓度相似。结论是,这些结果以及舒巴坦加氨苄西林的抗菌特性支持将这种联合用药作为治疗细菌性脑膜炎的替代方案进行评估。